Develops drugs for treatment-resistant depression.
Mar 2026Revenue $1.99M/yrExpenses $8.72M/yr
No trendCash runway ≈ 4 months from Jun 2026
Figures by year
When will Korsana Biosciences be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Mar 2026, revenue was $1.99M and expenses $8.72M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $2.07M | $7.05M | −$4.97M |
| Dec 2024 | $2.00M | $5.63M | −$3.63M |
| Dec 2023 | $0.00 | $13.0M | −$13.0M |
| Dec 2022 | $297K | $18.8M | −$18.5M |
| Dec 2021 | $3.94M | $59.1M | −$55.2M |
| Dec 2020 | $2.30M | $83.6M | −$81.3M |
| Dec 2019 | $4.51M | $130M | −$125M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.